Further investigation found that these LADA patients demonstrated progressively increasing C-peptide levels and slightly decreasing HbA1c levels after linagliptin-metformin treatment compared to the baseline levels [38], hinting at a possible therapeutic effect of DPP-4 inhibitors on T1DM. This evidence concerns the gene DPP4 and type 1 diabetes mellitus.